LYSOGENE financials
LYSOGENE
969500T64RILK1RD0852 | Line item | 2021 | 2020 |
|---|---|---|
| Income statement | ||
| Other income | €3.5M | €3.2M |
| Operating expenses | €20.5M | €21.7M |
| Operating profit (EBIT) | -€13.3M | -€5.1M |
| Net finance income / (cost) | -€318.0K | -€14.0K |
| Finance costs | €444.0K | €323.0K |
| Income tax expense | €0 | €0 |
| Profit for the year | -€13.6M | -€5.1M |
| Total comprehensive income | -€13.1M | -€5.2M |
| Per share | ||
| Basic EPS | €-0.81 | €-0.32 |
| Free cash flow / share | €-0.86 | €-0.91 |
| Cash flow statement | ||
| Net cash from operating activities | -€14.4M | -€14.5M |
| Net cash from investing activities | -€195.0K | -€34.0K |
| Purchase of PP&E (capex) | €16.0K | €33.0K |
| Purchase of intangibles | €270.0K | €0 |
| Net cash from financing activities | €8.2M | €6.8M |
| Proceeds from borrowings | €7.6M | €0 |
| Repayments of borrowings | €171.0K | €320.0K |
| Balance sheet | ||
| Total assets | €19.8M | €28.4M |
| Non-current assets | €2.3M | €2.4M |
| Property, plant & equipment | €283.0K | €326.0K |
| Right-of-use assets | €1.1M | €1.3M |
| Current assets | €17.5M | €26.0M |
| Cash & equivalents | €12.3M | €18.8M |
| Total equity | -€4.4M | €6.8M |
| Non-current liabilities | €9.6M | €1.8M |
| Long-term borrowings | €8.6M | €276.0K |
| Lease liabilities (non-current) | €966.0K | €1.1M |
| Current liabilities | €14.5M | €19.8M |
| Lease liabilities (current) | €173.0K | €171.0K |
| Derived metrics | ||
| Free cash flow | -€14.5M | -€14.5M |
| Operating margin | -356.2% | -38.0% |
| Net margin | -364.8% | -38.1% |
| Return on equity | 310.8% | -74.9% |
| Cash conversion ratio | 1.06× | 2.85× |
| Capex coverage | -902.63× | -438.91× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense | €191.0K | €193.0K |
| Adjustments For Provisions | -€968.0K | -€582.0K |
| Adjustments For Reconcile Profit Loss | -€833.0K | -€9.4M |
| Adjustments For Sharebased Payments | €1.9M | €1.9M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €12.3M | €18.8M |
| Changes In Equity | €0 | €0 |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €181.0K | €166.0K |
| Current Provisions | €63.0K | €1.2M |
| Equity and Liabilities | €19.8M | €28.4M |
| Finance Income | €126.0K | €309.0K |
| Increase Decrease In Cash and Cash Equivalents | -€6.4M | -€7.7M |
| Increase Decrease In Number of Shares Outstanding | 0.4M | 3.2M |
| Increase Decrease In Working Capital | €2.2M | €11.1M |
| Increase Decrease Through Sharebased Payment Transactions | €1.9M | €1.9M |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | €0 |
| Increase Decrease Through Treasury Share Transactions | €25.0K | — |
| Intangible Assets Other Than Goodwill | €272.0K | €133.0K |
| Issued Capital | €5.2M | €5.1M |
| Noncurrent Financial Assets | €164.0K | €220.0K |
| Noncurrent Provisions | €99.0K | €408.0K |
| Number of Shares Outstanding | 17.2M | 16.8M |
| Other Adjustments For Noncash Items | €0 | €1.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €312.0K | -€70.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €481.0K | -€70.0K |
| Other Current Assets | €5.2M | €7.2M |
| Other Current Liabilities | €9.7M | €13.3M |
| Other Inflows Outflows of Cash Classified As Investing Activities | €91.0K | -€1.0K |
| Other Noncurrent Assets | €450.0K | €450.0K |
| Proceeds From Government Grants Classified As Financing Activities | €710.0K | €0 |
| Proceeds From Issuing Shares | €26.0K | €7.2M |
| Research and Development Expense | €15.7M | €16.3M |
| Reserve of Exchange Differences On Translation | €0 | €0 |
| Revenue and Operating Income | €7.2M | €16.6M |
| Revenue From Contracts With Customers | €3.7M | €13.4M |
| Sale Or Issue of Treasury Shares | — | €25.0K |
| Selling General and Administrative Expense | €4.8M | €5.4M |
| Share Issue Related Cost | — | €579.0K |
| Share Premium | €12.5M | €54.6M |
| Trade and Other Payables To Trade Suppliers | €4.4M | €5.0M |
Every line item above is a fact tagged in LYSOGENE's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.